|
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
|
Jan 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Consider Allogeneic Bone Marrow Transplantation for Older, Fit Patients with Aplastic Anemia
|
Jan 2019
|
Biol Blood Marrow Transplant
|
aplastic anemia
|
|
Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
|
Jan 2019
|
Crit Rev Oncol Hematol
|
myelodysplastic syndromes (MDS)
|
|
Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant.
|
Jan 2019
|
Crit Rev Oncol Hematol
|
myelodysplastic syndromes (MDS)
|
|
Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates
|
Jan 2019
|
Semin Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry
|
Jan 2019
|
Am J Hematol
|
aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.
|
Dec 2018
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
|
Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
|
Nov 2018
|
Hematology Am Soc Hematol Educ Program
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.
|
Oct 2018
|
Curr Oncol
|
myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy
|
Jul 2018
|
Expert Rev Hematol
|
myelodysplastic syndromes (MDS)
|
